Benefits
Discover the transformative benefits of Lifespin’s cutting-edge technology. Our platform leverages precise metabolomic insights to enable comprehensive prevention, accurate diagnosis, and effective enhancement of therapies. Explore how Lifespin is revolutionizing healthcare with real-time, disease-agnostic, and hypothesis-free health monitoring and management.
Prevention, diagnosis, and enhancement of therapies
Enabled by an AI information layer created through precise metabolomic insights.
Prevention
Comprehensively tracking organ functions in real-time while employing a disease-agnostic and hypothesis-free methodology for the detection of illnesses.
Diagnosis
Detecting diseases specifically in an agnostic manner across oncology, neurology and inflammatory indications early on and potentially even before onset.
Therapy
Stratifying patients, and monitoring of patients during treatment and in aftercare by detecting the patient’s responses to treatment.
Metabolism – a gateway to understand human health
Metabolomic profiles are dynamic networks that we use to understand human health
Driving deep health and enabling affordable precision medicine
Combining detection technology and AI to build the metabolomic digital twin
Cyber-physical system:
Transforming analog blood samples to digital blood samples for health tests
Advanced detection:
Utilization of NMR and AI to digitally capture a comprehensive and quantitative metabolomic profile representing health status
Proprietary digital biobank:
A curated database comprising ample metadata and consisting of 240,000+ human datasets representing age and sex-specific metabolomes of healthy individuals and 700+ diseases
AI-enabled in-silico precision medicine:
Development of a “Metabolomic Digital Twin” for personalized in-silico health assessment through medical algorithms utilizing the lifespin database
Nobel Laureate
Prof. Dr. James Rothman
Sterling Professor of Cell Biology,
Yale University, Physiology/Medicine
Surpassing industry standards to redefine excellence
lifespin covers a broader target population at lower cost than illumina/ GRAIL
|
| |
|---|---|---|
Accessible Biomarkers
| Hundreds of clinical metabolomic parameters with countless quantitative correlations | ctDNA |
Information
| Metabolomic — real-time status of human health (What is actually happening or will happen) | Genomic — pathological DNA activity (What may happen or What should happen) |
Assumption
| Quantitative metabolic profiling becomes method of choice for assessment and diagnosis of health conditions | ctDNA screening becomes definitive analyte of cancer and defines origin of tumor |
Potential Outcome
| GRAIL is one of the leading cancer diagnostics companies | |
Addressable Market*
| $20B – $400B+ | $20B – $200B |
Targeted Population*
| Patients with metabolic ($18B), inflammatory ($2B), cardiovascular ($15.8B), neurological diseases ($12.9B), cancer ($214B), clinical trial cohorts ($54B), and corporate health ($87.2B | Cancer patients |
Test Price
| $50 – 500+ | $500 – 1000 |
Test Frequency
| 1 – 24 times per year | Once every 2 years |
